Transcriptomic Screening Identifies Gene That Slows Frailty Progression and Cellular Stress

A Nature Aging study published on 2026-10-01 from George Church’s group at Harvard Medical School and the Wyss Institute reported a screening platform that identified SRSF1 as a candidate for aging research. The work included computational biology collaborators affiliated with the Basque Research and Technology Alliance.

SRSF1 showed benefits in the study’s aging mice

The researchers report that inducible SRSF1 expression was associated with a 14% extension in median lifespan and a 44% reduction in frailty progression in their mouse experiment. These outcomes followed a screen based on gene-expression patterns in human fibroblasts, where SRSF1 also shifted transcriptional signatures toward a youthful state. The central result connects a molecular screening method with follow-up outcomes relevant to both lifespan and healthspan. It provides a candidate gene for further study and a way to search for others.

Evidence setting: In vitro experiments in human fibroblasts and animal experiments in aging mice.

Gene-expression patterns supplied the starting point

The study used gene-expression patterns as its measurable starting point. According to the authors’ abstract, the team developed an interpretable transcriptomic age predictor in human fibroblasts and used it in a cDNA overexpression screen. In this design, the age-related readout helped identify genes worth testing further.

The predictor helped choose genes for follow-up

The word “transcriptomic” matters because it identifies what the model was reading: patterns of gene expression. The screen was designed around an age predictor built in fibroblasts. Candidate genes were then assessed through that selected readout.

The intervention in this stage was increased expression of candidate genes. That is why the screen is more than a catalogue of age-associated patterns: it tests whether manipulating a candidate changes the selected readout. The result gives researchers a reason to carry a gene forward into additional experiments.

This creates a practical distinction between a tool for ranking candidates and the candidate itself. The predictor supplied a way to search. SRSF1 became a subject of additional experiments after emerging from that search.

For readers following biological-age measurements, the useful question is which outcome sits behind each claim. Here, the screening outcome was a gene-expression pattern in fibroblasts. The later experiments asked additional questions about cellular features and aging mice.

SRSF1 changed several aging-related features in cells

In the cell experiments, the authors report that inducing SRSF1 shifted transcriptional signatures toward a youthful state. They also observed reductions in cellular senescence, proteostatic stress and inflammatory signaling. Harvard Medical School’s account describes the inflammatory component as “inflammaging.”

These findings give the candidate more context than an age-prediction score alone. The expression signature describes one molecular pattern. The senescence and stress findings describe other features measured in the experiments. Reading those outcomes separately helps explain why the candidate warrants closer attention.

Preserving cellular identity was another reported feature of the cell work. The authors describe expression patterns becoming more youthful without the tested cells losing their identity. That gives the study two distinct questions to follow: how aging-associated features change and how the cell’s existing identity is maintained during those changes.

The senescence result also connects the work to questions about senescent-cell accumulation. Within this study, however, the relevant observation is specific: the authors reported less senescence under the tested cell conditions. The results support investigating how SRSF1-related expression changes interact with these aging-associated features.

Mouse follow-up added frailty and survival outcomes

The animal work supplied a different kind of follow-up. The paper’s abstract describes inducible SRSF1 expression in aging mice, and it reports both frailty progression and median lifespan. Those are the outcomes behind the study’s healthspan and longevity claims.

A result on frailty progression concerns how the animals’ frailty changed during the experiment. A median-lifespan result concerns survival. Keeping the two outcomes separate makes the finding easier to interpret: the researchers reported a slower progression of frailty alongside a longer median lifespan.

The median-lifespan wording also deserves to be preserved in any summary of the study. Reporting only that a gene “extends lifespan” removes the measured outcome and the animal setting. A precise account keeps the species and the survival measure attached to the result rather than treating the percentage as a general property of SRSF1.

This sequence is the platform’s main contribution. It moved from an age-related gene-expression readout to a selected candidate and then to additional cellular and animal tests. The strength of that approach is its ability to generate a testable research lead.

The evidence leaves important questions unresolved

The findings warrant follow-up, but the interpretation depends on the study’s experimental scope and disclosed interests. The main qualifications belong alongside the reported outcomes:

• The mouse experiment was small. The results came from small mouse groups. That makes larger replication studies important for judging how consistently the frailty and survival findings recur.
• Transcriptomic age was a screening readout. The sources do not establish that transcriptomic age is equivalent to functional age. A shift in the model’s score should therefore be read as a screening result rather than a complete measure of tissue health.
• Human treatment outcomes were not reported. Human-derived fibroblasts supplied the cell model, while the healthspan and lifespan outcomes came from mice. The reported percentages are findings from this experiment and are not estimates of a benefit in people.
• Preserved cellular identity does not settle safety. The authors’ cell finding leaves broader questions about long-term safety and dose unresolved. These questions require dedicated experiments rather than an assumption that a youthful expression pattern is safe.
• Delivery and tissue effects remain open questions. The Wyss Institute’s account reports that SRSF1 primarily accumulated in the liver after delivery. That distribution matters when assessing effects across different tissues and organisms.
• Protocol wording requires care. Harvard’s account describes gene delivery to aging mice, while the paper’s abstract describes “inducible SRSF1 expression.” The study paper is the stronger source for precise animal-protocol details.
• Some authors have patent and commercial interests. Harvard disclosed that several authors are inventors on a patent application covering SRSF1 and other factors. It also reported that Alexandru Plesa and George Church are cofounders of RegulaBio and hold equity in the early-stage company developing therapeutics for age-related diseases. Those interests are relevant context rather than evidence that the findings are invalid.

Harvard lists support from the Aging and Longevity-Related Research Fund and the Astera Fund at the Silicon Valley Community Foundation. Additional funding came from the Wyss Institute Synthetic Biology Platform and Spain’s Ministry of Science and Innovation.

The practical takeaway is to assess the platform and its leading candidate as separate research outputs. The platform offers a method for finding genes to investigate. SRSF1 now has cellular and mouse findings to test more rigorously. Personal decisions about emerging interventions belong with qualified care rather than a conversion of animal results into a treatment plan.

Replication and safety testing should come next

The next research priority should be replication in larger mouse studies, with tissue-specific function and long-term safety assessed before any move toward testing SRSF1-based interventions in people.

How AgeAmaze helps

A mouse lifespan result becomes a misleading longevity claim when its experimental setting disappears, a distinction AgeAmaze keeps visible in its research-led coverage. For adults assessing emerging interventions, the publication explains biological findings alongside their limits so that promising animal data are not mistaken for established benefits in people.

Read the research

Sources

1. New Screening Platform Helps Identify Genes With Tissue ...
2. Transcriptomic reprogramming screen identifies SRSF1 as ...
3. Reversing age by reprogramming gene expression networks